Micardis

Telmisartan

Adults w/ essential HTN. Prevention of CV morbidity & mortality in adults ≥55 yr at high risk of CV disease.

Essential HTN Recommended dose: 40 mg once daily. May be increased to max of 80 mg once daily if target BP is not achieved. Prevention of CV morbidity & mortality Recommended dose: 80 mg once daily. Hepatic impairment Max: 40 mg once daily.

May be taken with or without food.

Hypersensitivity. Biliary obstructive disorders. Concomitant use of aliskiren in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). Severe hepatic impairment. 2nd & 3rd trimesters of pregnancy. Lactation.

Hyperkalaemia may occur especially in presence of renal impairment &/or heart failure; monitor serum K. Concomitant use w/ K-sparing diuretics, K supplements, salt substitutes containing K or other medical products that may increase K level (eg, heparin, etc). Symptomatic hypotension in vol &/or Na-depleted patients. Renovascular HTN. Periodically monitor K & creatinine serum levels in patients w/ impaired renal function. Dual blockade of renin-angiotensin-aldosterone system (eg, adding ACE inhibitor or direct renin-inhibitor aliskiren to ARBs) is not recommended. Other conditions w/ stimulation of the renin-angiotensin-aldosterone system. Not recommended in patients w/ primary aldosteronism. Patients suffering from aortic or mitral stenosis or obstructive hypertrophic cardiomyopathy. Increased risk of fatal MI & unexpected CV death in diabetic patients w/ additional CV risk (eg, patients w/ DM & CAD). Undergo appropriate diagnostic evaluation (eg, exercise stress testing) to detect & treat CAD before initiating treatment. Less effective in lowering BP in black people. Possible MI or stroke in patients w/ ischaemic cardiopathy or CV disease due to excessive reduction of BP. Syncope or vertigo may occur when driving vehicles or operating machinery. Mild to moderate hepatic impairment. Not recommended during 1st trimester of pregnancy. Childn <18 yr.

Sepsis (including fatal outcome), URTI, UTI (including cystitis); thrombocytopenia, anaemia, eosinophilia; anaphylactic reaction, hypersensitivity; hyperkalaemia, hypoglycaemia (in diabetic patients), hyponatraemia; depression, anxiety, insomnia; syncope (faint); visual impairment; vertigo; bradycardia, tachycardia; hypotension, orthostatic hypotension; dyspnoea; abdominal pain & discomfort, diarrhoea, vomiting, dyspepsia, dry mouth, flatulence; abnormal hepatic function/liver disorder; angioedema (including fatal outcome), drug & toxic skin eruption, urticaria, eczema, erythema, rash, pruritus, hyperhidrosis; arthralgia, back, extremity (leg) & tendon (tendonitis-like symptoms) pain, muscle spasms, myalgia; renal impairment (including acute kidney injury); chest pain, asthenia, flu-like illness; increased hepatic enzyme, blood creatinine, blood creatinine phosphokinase & blood uric acid, decreased Hb.

May increase hypotensive effect of other antihypertensive agents. Increased median plasma trough conc of digoxin. Increased AUC_0-24 & C_max of ramipril & ramiprilat. Reversible increase in serum conc & toxicity of lithium. Potential acute renal insufficiency in dehydrated patients when concomitantly used w/ NSAIDs (eg, ASA at anti-inflammatory dosage regimens, COX-2 inhibitors & non-selective NSAIDs). Reduced effect of antihypertensive drugs w/ NSAIDs.

Angiotensin II Antagonists

C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx